Key takeaways
- Altimmune’s pemvidutide reduced weekly heavy drinking days by 4.2 days in a Phase 2 trial, compared to 2.75 days for placebo.
- Over 42% of patients taking the investigational drug achieved complete abstinence from heavy drinking by week 24.
- Objective blood tests confirmed a robust reduction in alcohol intake, bypassing the reliability issues of patient self-reporting.
- Patients on pemvidutide also experienced an average of 8.7% weight loss and improved liver fibrosis markers.
What happened
Altimmune’s investigational obesity drug, pemvidutide, significantly reduced heavy drinking days in patients with moderate-to-severe alcohol use disorder (AUD) during a Phase 2 trial. The clinical trial, named RECLAIM, evaluated the dual-agonist weekly injection over 24 weeks alongside behavioral therapy. The data was presented by lead researcher Dr. Henry R. Kranzler of the Perelman School of Medicine at the University of Pennsylvania during the American Association for the Study of Liver Diseases (AASLD) annual meeting in Denver.
Why it matters
This clinical milestone demonstrates that next-generation weight-loss medications have therapeutic benefits extending far beyond weight management and diabetes. For US consumers, these findings suggest a future where medical weight-loss telehealth platforms may officially prescribe dual-agonist therapies to treat addiction and alcohol dependency.
While the FDA has approved three therapies to treat AUD, very few individuals with the disorder currently access those options. If approved for AUD, pemvidutide could establish a structured clinical pathway for patients to address both metabolic dysfunction and chemical dependency through a single, weekly subcutaneous injection prescribed online.
What the data says
The Phase 2 RECLAIM trial randomized 100 participants with moderate-to-severe AUD to receive either once-weekly subcutaneous pemvidutide or a placebo for 24 weeks. The study participants, who had an average body mass index (BMI) of approximately 32, were heavy drinkers averaging 5.6 to 5.9 heavy drinking days (HDDs) per week at baseline.
According to the data presented at the conference:
- Reduction in Heavy Drinking: Weekly HDDs decreased by 4.20 days with pemvidutide compared to 2.75 days with the placebo group.
- Complete Abstinence: 42.2% of patients receiving pemvidutide achieved zero heavy drinking days by week 24, compared to just 17.4% in the placebo group.
- Objective Biomarker Success: Pemvidutide patients showed a robust decrease in serum phosphatidylethanol (PEth)—an objective blood biomarker for alcohol consumption—dropping by 153.4 ng/mL, while the placebo group actually rose by 22.0 ng/mL.
- Secondary Metabolic Benefits: Patients taking pemvidutide lost an average of 8.7% of their body weight, compared to a weight gain of 0.4% in the placebo group. They also showed significant improvements in liver health, measured by a drop in Fibrosis-4 scores.
- Side Effect Profile: Mild-to-moderate gastrointestinal issues were the most common adverse events, affecting 62% of the pemvidutide group versus 34% of the placebo group.
How it compares
Unlike single-hormone GLP-1 drugs like Wegovy (semaglutide), pemvidutide is a balanced 1:1 dual glucagon/GLP-1 receptor agonist. While standard GLP-1s slow digestion to promote fullness, the addition of glucagon receptor activity directly targets liver fat, inflammation, and energy expenditure.
Currently, patients looking to purchase GLP-1 medications through online telehealth providers typically seek prescriptions for weight loss or type 2 diabetes. If you buy compounded semaglutide or branded options like Zepbound via cash-pay providers or platforms, the treatment is strictly indicated for weight management.
By targeting the brain's reward centers alongside metabolic pathways, pemvidutide aims to compete not just on weight loss, but as a dual-purpose health intervention. This positions it as a direct competitor to Eli Lilly’s pipeline candidates like retatrutide, which is also demonstrating broad clinical utility. For a comparison of existing options, check out our guide on semaglutide vs tirzepatide.
How this fits the bigger picture
The RECLAIM trial results align with a growing body of research showing that GLP-1 receptor agonists can treat systemic diseases beyond obesity. For example, clinical trials have shown next-gen molecules can treat sleep apnea, as covered in our report on how Lilly's oral GLP-1 treats sleep apnea, and can lower post-surgical risks, which we explored in our analysis of the Mayo Clinic liver transplant study.
Historically, clinical weight-loss guidelines relied strictly on body mass index to determine who qualified for these expensive medications. However, as next-generation drugs prove they can treat addiction, liver fibrosis, and cardiovascular disease, the clinical framework is shifting. This clinical evolution supports the recent Lancet proposal to drop BMI standards in favor of a "clinical obesity" model, which could drastically alter how US insurance companies and online health platforms screen patients for GLP-1 access.
What happens next
Altimmune is expected to continue clinical development for pemvidutide, leveraging these Phase 2 results to design Phase 3 trials targeting both metabolic health and alcohol use disorder. Because there is currently a high unmet need for effective AUD treatments, positive late-stage data could fast-track pemvidutide's regulatory path.
In the meantime, patients seeking weight-loss treatments can search for and compare current telehealth providers, drug pricing, and therapy options to find the best fit for their needs.
Disclaimer: CompareRx does not provide medical advice. Always consult a licensed healthcare provider before starting any new medication or treatment plan.

